Clinical Trial · NCT04693169

[Al18F]PSMA137 PET/CT Imaging for PSMA-Positive Cancer Patients

Overview

To investigate the radioactive uptake of [Al 18 F]PSMA137 in PCa patients, and evaluate the ability of [Al 18 F]PSMA137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa).To provide an approach for screening patients high expression of PSMA, efficacy monitoring, drug resistance and early warning of recurrence and metastasis to achieve the individualized antitumor treatment of targeted drugs.

Sponsor

Peking University Cancer Hospital & Institute

Phase

N/A

Contacts

Yanan Ren

yananren123@126.com

010-88196495

Hua Zhu (Associate Professor)

zhuhuabch@pku.edu.cn

010-88196495

ClinicalTrials.gov

NCT04693169

Drug / Compound

Isotope(s):
Target(s):